Ionis Pharmaceuticals IONS Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's royalty — revenue?
- Ionis Pharmaceuticals (IONS) reported royalty — revenue of $58.32M in Q1 2026.
- How has Ionis Pharmaceuticals's royalty — revenue changed year-over-year?
- Ionis Pharmaceuticals's royalty — revenue decreased by 9.1% year-over-year, from $64.17M to $58.32M.
- What is the long-term trend for Ionis Pharmaceuticals's royalty — revenue?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's royalty — revenue has grown at a 2.3% compound annual growth rate (CAGR), from $272.8M to $285.53M.
- What does royalty — revenue mean?
- Revenue earned from licensing fees and royalties paid by partners for the use of the company's drug development technology.
- How do you interpret royalty — revenue?
- An increase indicates higher commercial adoption and sales volume of partner-marketed drugs utilizing the company's technology, while a decrease may signal patent expirations, loss of market share, or reduced partner sales performance.
- How does royalty — revenue compare across companies?
- Comparable to royalty revenue streams in other biotechnology or pharmaceutical firms that utilize a licensing-heavy business model, often benchmarked against total licensing revenue or royalty percentage agreements.